This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Over 8.8?million Indians aged 60 and above currently live with dementia,
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
Subscribe To Our Newsletter & Stay Updated
